De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Rimawi, 2015, Targeting HER2 for the treatment of breast cancer, Annu Rev Med, 66, 111, 10.1146/annurev-med-042513-015127

Gutierrez, 2011, HER2: biology, detection, and clinical implications, Arch Pathol Lab Med, 135, 55, 10.5858/2010-0454-RAR.1

Citri, 2006, EGF-ERBB signalling: towards the systems level, Nat Rev Mol Cell Biol, 7, 505, 10.1038/nrm1962

Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3

Swain, 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 372, 724, 10.1056/NEJMoa1413513

Rimawi, 2011, Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts, Clin Cancer Res, 17, 1351, 10.1158/1078-0432.CCR-10-1905

Arpino, 2007, Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy, J Natl Cancer Inst, 99, 694, 10.1093/jnci/djk151

Wang, 2011, Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation, Breast Cancer Res, 13, R121, 10.1186/bcr3067

Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9

Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 18(4):545–554.

Rimawi, 2013, Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006, J Clin Oncol, 31, 1726, 10.1200/JCO.2012.44.8027

Rexer, 2012, Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications, Crit Rev Oncog, 17, 1, 10.1615/CritRevOncog.v17.i1.20

Tortora, 2011, Mechanisms of resistance to HER2 target therapy, J Natl Cancer Inst Monogr, 2011, 95, 10.1093/jncimonographs/lgr026

Kessler, 2012, Resistance to HER2-targeted therapy in HER2+ breast cancer, Clin Med Rev Women's Health, 4, 15

Puglisi, 2012, Overcoming treatment resistance in HER2-positive breast cancer: potential strategies, Drugs, 72, 1175, 10.2165/11634000-000000000-00000

Weinstein, 2002, Cancer. Addiction to oncogenes–the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096

Carey, 2016, Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib, J Clin Oncol, 34, 542, 10.1200/JCO.2015.62.1268

Ng, 2015, Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification, Genome Biol, 16, 107, 10.1186/s13059-015-0657-6

Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984

Cerami, 2012, The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095

Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088

Bose, 2013, Activating HER2 mutations in HER2 gene amplification negative breast cancer, Cancer Discov, 3, 224, 10.1158/2159-8290.CD-12-0349

Boulbes, 2015, HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer, Mol Oncol, 9, 586, 10.1016/j.molonc.2014.10.011

Zuo, 2016, Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer, Clin Cancer Res, 22, 4859, 10.1158/1078-0432.CCR-15-3036

Xu, 2017, HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer, Clin Cancer Res, 10.1158/1078-0432.CCR-16-2191

Jeselsohn, 2015, ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer, Nat Rev Clin Oncol, 12, 573, 10.1038/nrclinonc.2015.117

Christianson, 1998, NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer, Cancer Res, 58, 5123

Molina, 2001, Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res, 61, 4744

Molina, 2002, NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer, Clin Cancer Res, 8, 347

Saez, 2006, p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer, Clin Cancer Res, 12, 424, 10.1158/1078-0432.CCR-05-1807

Scaltriti, 2007, Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer, J Natl Cancer Inst, 99, 628, 10.1093/jnci/djk134

Zhang, 2016, HER3/ErbB3, an emerging cancer therapeutic target, Acta Biochim Biophys Sin (Shanghai), 48, 39, 10.1093/abbs/gmv103

Vaz-Luis, 2013, Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?, Ann Oncol, 24, 283, 10.1093/annonc/mds286

Xia, 2006, A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer, Proc Natl Acad Sci U S A, 103, 7795, 10.1073/pnas.0602468103

Giuliano, 2015, Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy, Clin Cancer Res, 21, 3995, 10.1158/1078-0432.CCR-14-2728

Fumagalli, 2016, RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial, JAMA Oncol, 3, 227, 10.1001/jamaoncol.2016.3824

Schneeweiss, 2013, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Ann Oncol, 24, 2278, 10.1093/annonc/mdt182

Untch, 2012, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial, Lancet Oncol, 13, 135, 10.1016/S1470-2045(11)70397-7

Mayer, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu Rev Med, 67, 11, 10.1146/annurev-med-062913-051343

Fruman, 2014, PI3K and cancer: lessons, challenges and opportunities, Nat Rev Drug Discov, 13, 140, 10.1038/nrd4204

Fu, 2014, Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase, Breast Cancer Res, 16, 430, 10.1186/s13058-014-0430-x

Berns, 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, 12, 395, 10.1016/j.ccr.2007.08.030

Eichhorn, 2008, Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235, Cancer Res, 68, 9221, 10.1158/0008-5472.CAN-08-1740

Chandarlapaty, 2012, Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer, Clin Cancer Res, 18, 6784, 10.1158/1078-0432.CCR-12-1785

Fujita, 2006, PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer, Br J Cancer, 94, 247, 10.1038/sj.bjc.6602926

O'Brien, 2010, Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib, Mol Cancer Ther, 9, 1489, 10.1158/1535-7163.MCT-09-1171

Faratian, 2009, Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab, Cancer Res, 69, 6713, 10.1158/0008-5472.CAN-09-0777

Stemke-Hale, 2008, An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer, Cancer Res, 68, 6084, 10.1158/0008-5472.CAN-07-6854

Pogue-Geile, 2015, Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial, J Clin Oncol, 33, 1340, 10.1200/JCO.2014.56.2439

Loi, 2013, Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer, J Natl Cancer Inst, 105, 960, 10.1093/jnci/djt121

Loibl, 2016, PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab, Ann Oncol, 27, 1519, 10.1093/annonc/mdw197

Baselga, 2014, Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer, J Clin Oncol, 32, 3753, 10.1200/JCO.2013.54.5384

Cizkova, 2013, Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab, Br J Cancer, 108, 1807, 10.1038/bjc.2013.164

Jensen, 2012, PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab, Ann Oncol, 23, 2034, 10.1093/annonc/mdr546

Nagata, 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022

Saal, 2005, PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma, Cancer Res, 65, 2554, 10.1158/0008-5472-CAN-04-3913

Pandolfi, 2004, Breast cancer–loss of PTEN predicts resistance to treatment, N Engl J Med, 351, 2337, 10.1056/NEJMcibr043143

Crowder, 2004, Successful targeting of ErbB2 receptors-is PTEN the key?, Cancer Cell, 6, 103, 10.1016/j.ccr.2004.08.001

Ingold Heppner, 2016, Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer, Clin Cancer Res, 22, 5747, 10.1158/1078-0432.CCR-15-2338

Gallardo, 2012, Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas, Br J Cancer, 106, 1367, 10.1038/bjc.2012.85

Esteva, 2010, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer, Am J Pathol, 177, 1647, 10.2353/ajpath.2010.090885

Wang, 2011, PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib, BMC Cancer, 11, 248, 10.1186/1471-2407-11-248

Gori, 2009, EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab, Ann Oncol, 20, 648, 10.1093/annonc/mdn681

Yonemori, 2010, Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy, J Surg Oncol, 101, 222, 10.1002/jso.21486

Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112

Stern, 2015, PTEN loss Is associated with worse outcome in HER2-amplified breast cancer patients but Is not associated with trastuzumab resistance, Clin Cancer Res, 21, 2065, 10.1158/1078-0432.CCR-14-2993

Park, 2014, Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment, Br J Cancer, 110, 384, 10.1038/bjc.2013.757

Perez, 2013, Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial, J Clin Oncol, 31, 2115, 10.1200/JCO.2012.42.2642

Dave, 2011, Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers, J Clin Oncol, 29, 166, 10.1200/JCO.2009.27.7814

Xia, 2007, Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers, Cancer Res, 67, 1170, 10.1158/0008-5472.CAN-06-2101

Nuciforo, 2015, Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status, Ann Oncol, 26, 1494, 10.1093/annonc/mdv175

Lu, 2003, Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades, J Biol Chem, 278, 40057, 10.1074/jbc.M303621200

Wang, 2009, Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton, Cancer Res, 69, 475, 10.1158/0008-5472.CAN-08-2649

Liang, 2010, Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation, Cancer Cell, 18, 423, 10.1016/j.ccr.2010.10.025

Zhang, 2011, Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways, Nat Med, 17, 461, 10.1038/nm.2309

Takeda, 2017, Yes1 signaling mediates the resistance to Trastuzumab/Lapatinib in breast cancer, PLoS One, 12, e0171356, 10.1371/journal.pone.0171356

Salgado, 2015, Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial, JAMA Oncol, 1, 448, 10.1001/jamaoncol.2015.0830

Bianchini, 2015, Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Ann Oncol, 26, 2429, 10.1093/annonc/mdv395

Perez, 2016, Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer, JAMA Oncol, 2, 56, 10.1001/jamaoncol.2015.3239

Perez, 2015, Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial, J Clin Oncol, 33, 701, 10.1200/JCO.2014.57.6298

Dieci, 2016, Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial, Ann Oncol, 27, 1867, 10.1093/annonc/mdw262

Denkert, 2015, Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers, J Clin Oncol, 33, 983, 10.1200/JCO.2014.58.1967

Luen, 2017, Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study, Lancet Oncol, 18, 52, 10.1016/S1470-2045(16)30631-3

Tolaney, 2015, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 372, 134, 10.1056/NEJMoa1406281

2015, TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib, trastuzumab, with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer, vol. 75